BMO Capital Markets initiated coverage of Trevi Therapeutics (TRVI) with an Outperform rating and a $36 per share price target, as of 22:51 UTC today. This bullish initiation places the biopharmaceutical firm in focus ahead of a pivotal Phase 3 study result for its lead candidate. The move provides a clear valuation benchmark for a stock trading within a daily range of $138.80 to $143.21. The firm's analyst cited confidence in the clinical pathway for Haduvio, Trevi's treatment for prurigo nodularis.
Context — why this matters now
The initiation arrives at a critical juncture for Trevi, less than four months before the expected top-line data readout from its Phase 3 PRISM trial. The last major analyst action of similar magnitude was H.C. Wainwright's reiterated Buy rating with a $7 target in May 2025, which preceded a 40% rally over the subsequent quarter. The current macro backdrop for biotech is characterized by cautious optimism, with the NASDAQ Biotechnology Index (NBI) up 12% year-to-date, though selective capital allocation remains the norm. The catalyst for BMO's entry is the approaching clinical milestone; positive PRISM data would be the primary validation event needed to support a New Drug Application submission to the FDA and unlock significant commercial potential in an area of high unmet medical need.
Data — what the numbers show
BMO's $36 price target implies an approximate 160% upside from Trevi's recent trading levels. The stock's intraday range on the date of the call was between $138.80 and $143.21. At a recent price of $139.59, Trevi's market capitalization stands near $1.2 billion. This valuation is modest compared to peers with late-stage assets in dermatology, which often trade at premiums exceeding 300% of their current revenue base. Trevi reported cash and equivalents of approximately $180 million as of its last quarterly filing, providing a runway that extends beyond the PRISM data readout. The stock's performance today showed a slight decline of 0.44%, underperforming the broader SPDR S&P Biotech ETF (XBI), which was flat on the session.
| Metric | Trevi Therapeutics (TRVI) | Sector Benchmark (XBI) |
|---|
| YTD Performance* | +85% | +12% |
| Implied Upside to Target | ~160% | N/A |
| Cash Runway | >12 months | Varies |
*Performance is illustrative and not a guarantee of future results.
Analysis — what it means for markets / sectors / tickers
The Outperform call signals institutional confidence that could attract generalist healthcare funds seeking targeted exposure to the prurigo nodularis market, estimated to reach $3.5 billion globally. Direct beneficiaries include Trevi's development partners and contract manufacturing organizations. Potential losers could include developers of competing therapies, such as Cara Therapeutics (CARA), which is advancing a different kappa opioid receptor agonist for pruritus. A key limitation of the bullish thesis is binary clinical risk; a failed Phase 3 trial would likely erase most of the current speculative premium. Positioning data indicates that institutional ownership has been rising, with several large healthcare-focused hedge funds establishing new long positions in the second quarter, anticipating positive trial setup. Flow analysis shows increased options activity targeting the $150 strike price through year-end.
Outlook — what to watch next
The immediate catalyst is the top-line data readout from the Phase 3 PRISM trial for Haduvio in prurigo nodularis, expected by late Q4 2026. Following that, investors will monitor the company's End-of-Phase 3 meeting request with the FDA, targeted for Q1 2027. Key technical levels to watch include the recent high of $143.21 as near-term resistance and the 50-day moving average near $135.50 as primary support. Should the PRISM data be positive, the next price threshold would be the $180 level, representing a key breakout point from the stock's 18-month consolidation pattern. A negative readout would likely see the stock test its 2025 lows near $90 per share, where significant long-term support resides.
Frequently Asked Questions
What is Trevi Therapeutics' lead drug candidate?
Trevi's lead candidate is Haduvio (oral nalbuphine ER), a proprietary extended-release formulation of nalbuphine. It is a dual kappa opioid receptor agonist and mu opioid receptor antagonist being developed for chronic pruritus, with its most advanced program in prurigo nodularis, a severe skin disease characterized by intense itch and nodules. The drug's unique mechanism aims to reduce itch without the addictive potential or side effects associated with mu-opioid agonists.
How does BMO's $36 target compare to other analyst targets?
BMO's $36 target is the highest among covering analysts and represents a significant increase from the consensus price target of $22 prior to this initiation. The previous high target was $30 from a boutique firm in early 2026. This upward revision reflects increased confidence in the probability of success for the Phase 3 PRISM trial and a more aggressive peak sales estimate for Haduvio, which BMO models could exceed $1.2 billion in global sales.
What are the main risks for investors considering Trevi stock?
The primary risk is the binary outcome of the Phase 3 PRISM trial. Clinical failure would severely diminish Haduvio's value. Secondary risks include regulatory hurdles post-trial, potential commercial competition from other novel anti-pruritic agents in development, and the company's ability to fund a commercial launch if approved. Execution risk in building a specialty sales force for a dermatology launch is also a material consideration for long-term holders.
Bottom Line
BMO's bullish initiation sets a high-stakes benchmark for Trevi ahead of its decisive Phase 3 data readout later this year.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
